(Q41698172)

English

Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a

scientific article published on 12 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

7 October 2017

Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a (English)

1 reference

Europe PubMed Central

7 October 2017

Behçet's disease

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Özlem Aydinoglu-Candan

1

1 reference

Europe PubMed Central

7 October 2017

Bilge Araz-Erşan

2

1 reference

Europe PubMed Central

7 October 2017

Ahmet Gul

3

1 reference

Europe PubMed Central

7 October 2017

Selim Badur

4

1 reference

Europe PubMed Central

7 October 2017

Ilknur Tugal-Tutkun

5

1 reference

Europe PubMed Central

7 October 2017

publication date

12 December 2014

1 reference

Europe PubMed Central

7 October 2017

Graefe's Archive for Clinical and Experimental Ophthalmology

1 reference

Europe PubMed Central

7 October 2017

253

1 reference

Europe PubMed Central

7 October 2017

3

1 reference

Europe PubMed Central

7 October 2017

457-465

1 reference

Europe PubMed Central

7 October 2017

https://scigraph.springernature.com/pub.10.1007/s00417-014-2856-3

0 references

Behçet's disease as an autoinflammatory disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Autoimmunity vs autoinflammation in Behcet's disease: do we oversimplify a complex disorder?

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

The place of Behçet's syndrome among the autoimmune diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Type I interferon in organ-targeted autoimmune and inflammatory diseases

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Tracking interferon in autoimmunity

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Type I interferon: friend or foe?

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Cytokine therapeutics: lessons from interferon alpha

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

The use of interferon alpha in Behçet disease: review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Low-dose interferon alfa-2a therapy in severe uveitis associated with Behçet disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Interferon therapy for ocular disease

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Role of anti-interferon antibodies in breakthrough occurrence during alpha 2a and 2b therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Interferon therapy in rheumatic diseases: state-of-the-art 2010.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Anti-IFN autoantibodies are present in healthy Egyptian blood donors at low titer

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Evaluation of a multiplex bead-based screening assay for detection of binding antibodies to interferon-beta.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Interferon as a treatment for uveitis associated with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Immunopathogenic mechanisms of systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Genetics of Behçet's disease: lessons learned from genomewide association studies

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Intraocular cytokine environment in active Behçet uveitis.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Cytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitis.

1 reference

https://api.crossref.org/works/10.1007%2FS00417-014-2856-3

21 January 2018

Potential Infectious Etiology of Behçet's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving the reporting of clinical case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of binding anti-IFNbeta antibodies in IFNbeta-treated MS patients: lessons for the clinician and basic scientist

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of interferon alpha-2a therapy in patients with Behcet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon alfa combined with azathioprine for the uveitis of Behçet's disease: an open study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does the presence of serum autoantibodies influence the responsiveness to interferon-alpha 2a treatment in chronic hepatitis C?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha: a key factor in autoimmune disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Role of interferon anti body in predicting the response to interferon therapy in HCV patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of interferon-alfa therapy in patients with Behçet uveitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of human recombinant interferon- 2a (rhIFN- 2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral blood lymphocyte subsets in patients with chronic hepatitis C--effects of interferon treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/25500983

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00417-014-2856-3

1 reference

Europe PubMed Central

7 October 2017

release_fmgoglptpzeqplddxrvmyyjsai

1 reference

https://api.fatcat.wiki/v0/release/fmgoglptpzeqplddxrvmyyjsai

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

7 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41698172&oldid=1926044222"